ClinicalTrials.gg
TerminatedNCT05368558509 JPN SchzUpdated Oct 20, 2025Results posted

Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia

A Phase 3 interventional study of Cariprazine and Placebo in Schizophrenia, sponsored by AbbVie. Terminated at 52 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Why this study was terminated
Strategic considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing cariprazine in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. cariprazine · Schizophrenia.

Enrollment
19th of 23
34 · median 129
Started
2022
the only one that year
Phase 3
8 of 23
1 open now
Registered
18th of 23
by date
Lead sponsor
2 of 23
AbbVie

Among the 23 studies testing cariprazine in Schizophrenia, this one is the 19th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 3, and was the 18th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 23 studies testing cariprazine in Schizophrenia are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cariprazine

cariprazine: first FDA approval 2015 (VRAYLAR), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cariprazine in Schizophrenia, or all of them as a file.
02

Study summary

Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess how safe and effective cariprazine is in treating adult participants with schizophrenia in Japan and Taiwan. Adverse events and change in disease activity will be assessed.

Cariprazine (VRAYLAR) is an approved drug for the treatment of schizophrenia in the United States. In the first 6-week period, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to placebo. In the next 18-week period, participants will have the option to receive 1 of 3 doses of cariprazine. Approximately 250 adult participants, 18-65 years of age with schizophrenia will be enrolled in approximately 55 sites across Taiwan and Japan.

Participants will receive oral capsules of Cariprazine or placebo for the 6-week Double-blind Period (DBP). Upon completion of 6-week DBP, participants will be eligible to receive oral capsules of Cariprazine for additional 18 weeks in the Blinded Extension Period (BEP), followed by an 8-week safety follow-up period.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Read the detailed description

Per the final protocol amendment 3, the number of dosing arms in the 6-week DBP of the study changed from 3 to 2. Participants enrolled in the study through Protocol Amendment 2 and who were randomized to the arm that was eliminated, remained in that arm through DBP and their data are displayed by that arm for the DBP portion of the study in participant flow, baseline characteristics and safety sections. Data for all endpoints are presented as planned per final SAP.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Cariprazine
  • VRAYLAR
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with schizophrenia at least 1 year before .
  • Experienced a persistent psychotic episode within 2 months prior to informed consent requiring treatment modifications as judged by the investigator or sub-investigator.

Exclusion criteria

Exclusion Criteria:

- History of medical conditions or any other reason that the investigator (or subinvestigator) determines would interfere with the participant's participation in this study or would make the participant an unsuitable candidate to receive study drug.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Cariprazine

    Participants will receive cariprazine Dose A daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.

    Drug: Cariprazine

  • Placebo comparator
    Placebo

    Participants will receive placebo daily for 6 weeks. Upon completion of 6 week treatment period, participants will have option to receive cariprazine Dose B for 18 weeks.

    Drug: Cariprazine · Drug: Placebo

Interventions

  • Oral Capsule

    Also known as: VRAYLAR

  • DrugPlacebo

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 8 weeks following last dose of study drug (up to 32 weeks)

  2. Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6.

    Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) to Week 6

Secondary outcomes

  1. Change in CGI-S Score From Baseline (Wk 0) to Week 6

    Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) to Week 6

  2. Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6

    Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) to Week 6

  3. Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6

    Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) to Week 6

  4. Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6

    Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) to Week 6

  5. Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6

    Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) to Week 6

  6. Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24

    Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) and Week 6 to Week 24

  7. Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24

    Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) and Week 6 to Week 24

  8. Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24

    Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) and Week 6 to Week 24

  9. Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24

    Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) and Week 6 to Week 24

  10. Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24

    Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) and Week 6 to Week 24

  11. Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24

    Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

    Time frame: Baseline (Wk 0) and Week 6 to Week 24

07

Results

Posted Oct 20, 2025

Participant flow

Double Blind Period (DBP)
Participant flow — Double Blind Period (DBP)
MilestoneDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mgSF DBP PlaceboSF DBP Cariprazine 3 mgSF DBP Cariprazine 6 mgSF BEP Cariprazine 1.5 mgSF BEP Cariprazine 3 mgSF BEP Cariprazine 6 mg
Started16513000000000
Completed15411000000000
Not completed112000000000
Withdrew: Withdrawal by subject112000000000
Blinded Extension Period (BEP)
Participant flow — Blinded Extension Period (BEP)
MilestoneDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mgSF DBP PlaceboSF DBP Cariprazine 3 mgSF DBP Cariprazine 6 mgSF BEP Cariprazine 1.5 mgSF BEP Cariprazine 3 mgSF BEP Cariprazine 6 mg
Started00010410000000
Completed000847000000
Not completed000203000000
Withdrew: Withdrawal by subject000102000000
Withdrew: Study terminated by sponsor000100000000
Withdrew: Other000001000000
Safety Follow-up DBP (SF DBP)
Participant flow — Safety Follow-up DBP (SF DBP)
MilestoneDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mgSF DBP PlaceboSF DBP Cariprazine 3 mgSF DBP Cariprazine 6 mgSF BEP Cariprazine 1.5 mgSF BEP Cariprazine 3 mgSF BEP Cariprazine 6 mg
Started00000015411000
Completed000000514000
Not completed0000001037000
Safety Follow-up BEP (SF BEP)
Participant flow — Safety Follow-up BEP (SF BEP)
MilestoneDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mgSF DBP PlaceboSF DBP Cariprazine 3 mgSF DBP Cariprazine 6 mgSF BEP Cariprazine 1.5 mgSF BEP Cariprazine 3 mgSF BEP Cariprazine 6 mg
Started00000000010410
Completed00000000010410
Not completed000000000000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 8 weeks following last dose of study drug (up to 32 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mg
Number of Participants With Treatment Emergent Adverse Events (TEAEs)12210
PrimaryChange in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6.

Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) to Week 6
Reported as:
Mean · score on a scale
Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6.
score on a scaleDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mg
Change in SCI-PANSS Total Score From Baseline (Wk 0) to Week 6.-15.2 ± 12.21-5.6 ± 10.38-30.2 ± 17.47
Statistical analysis
  • DBP Placebo vs DBP Cariprazine 3 mg · Mean difference (final values): 9.6 · 95% CI -4.0 to 23.1
  • DBP Placebo vs DBP Cariprazine 6 mg · Mean difference (final values): -15.0 · 95% CI -28.7 to -1.4
SecondaryChange in CGI-S Score From Baseline (Wk 0) to Week 6

Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) to Week 6
Reported as:
Mean · score on a scale
Change in CGI-S Score From Baseline (Wk 0) to Week 6
score on a scaleDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mg
Change in CGI-S Score From Baseline (Wk 0) to Week 6-0.6 ± 0.92-0.4 ± 0.55-1.3 ± 1.25
Statistical analysis
  • DBP Placebo vs DBP Cariprazine 3 mg · Mean difference (final values): 0.2 · 95% CI -0.7 to 1.2
  • DBP Placebo vs DBP Cariprazine 6 mg · Mean difference (final values): -0.7 · 95% CI -1.7 to 0.3
SecondaryChange in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6

Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) to Week 6
Reported as:
Mean · score on a scale
Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6
score on a scaleDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mg
Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) to Week 6-4.7 ± 4.67-2.2 ± 3.35-8.7 ± 4.00
Statistical analysis
  • DBP Placebo vs DBP Cariprazine 3 mg · Mean difference (final values): 2.5 · 95% CI -2.5 to 7.5
  • DBP Placebo vs DBP Cariprazine 6 mg · Mean difference (final values): -4.0 · 95% CI -8.0 to 0.0
SecondaryChange in NSA-16 Total Score to Baseline (Wk 0) to Week 6

Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) to Week 6
Reported as:
Mean · score on a scale
Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6
score on a scaleDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mg
Change in NSA-16 Total Score to Baseline (Wk 0) to Week 6-3.2 ± 7.49-2.8 ± 9.20-14.5 ± 8.28
Statistical analysis
  • DBP Placebo vs DBP Cariprazine 3 mg · Mean difference (final values): 0.4 · 95% CI -8.9 to 9.7
  • DBP Placebo vs DBP Cariprazine 6 mg · Mean difference (final values): -11.3 · 95% CI -18.5 to -4.1
SecondaryChange in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6

Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) to Week 6
Reported as:
Mean · score on a scale
Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6
score on a scaleDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mg
Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) to Week 6-3.5 ± 3.86-0.2 ± 3.27-8.1 ± 5.30
Statistical analysis
  • DBP Placebo vs DBP Cariprazine 3 mg · Mean difference (final values): 3.3 · 95% CI -1.0 to 7.5
  • DBP Placebo vs DBP Cariprazine 6 mg · Mean difference (final values): -4.6 · 95% CI -8.9 to -0.4
SecondaryChange in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6

Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) to Week 6
Reported as:
Mean · score on a scale
Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6
score on a scaleDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mg
Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) to Week 6-3.8 ± 3.71-0.4 ± 3.78-9.1 ± 6.82
Statistical analysis
  • DBP Placebo vs DBP Cariprazine 3 mg · Mean difference (final values): 3.4 · 95% CI -0.9 to 7.7
  • DBP Placebo vs DBP Cariprazine 6 mg · Mean difference (final values): -5.3 · 95% CI -10.2 to -0.3
SecondaryChange in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24

Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) and Week 6 to Week 24
Reported as:
Mean · score on a scale
Change in SCI-PANSS Total Score From Baseline (Wk 0) and Week 6 to Week 24
score on a scaleBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mg
Baseline (Wk 0) to Week 24-19.2 ± 19.52-19.3 ± 30.09-22.5 ± 25.16
Week 6 to Week 24-4.0 ± 16.052.0 ± 4.586.0 ± 17.51
SecondaryChange in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24

Clinical Global Impression-Severity (CGI-S) is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The total CGI-S score can range from 1 to 7. A higher score indicates more severe illness. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) and Week 6 to Week 24
Reported as:
Mean · score on a scale
Change in CGI-S Score From Baseline (Wk 0) and Week 6 to Week 24
score on a scaleBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mg
Baseline (Wk 0) to Week 24-0.8 ± 0.84-1.3 ± 2.31-1.0 ± 0.82
Week 6 to Week 24-0.4 ± 1.140.0 ± 0.000.0 ± 0.82
SecondaryChange in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24

Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) and Week 6 to Week 24
Reported as:
Mean · score on a scale
Change in SCI-PANSS Positive Symptom Score From Baseline (Wk 0) and Week 6 to Week 24
score on a scaleBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mg
Baseline (Wk 0) to Week 24-5.2 ± 5.36-4.3 ± 7.51-6.8 ± 6.60
Week 6 to Week 24-0.2 ± 4.380.3 ± 0.581.5 ± 6.03
SecondaryChange in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24

Negative Symptom Assessment-16 (NSA-16) is a 16-item clinician-reported scale covering 5 areas or domains: communication, affect, social involvement, motivation, and retardation. It is designed to assess negative symptoms of patients with schizophrenia. Each item or behavior is rated on a 6-point scale ranging from 1 (not reduced) to 6 (severely reduced or absent). Higher values represent a worse outcome. The total NSA-16 score can range from 16 to 96. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) and Week 6 to Week 24
Reported as:
Mean · score on a scale
Change in NSA-16 Total Score From Baseline (Wk 0) and Week 6 to Week 24
score on a scaleBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mg
Baseline (Wk 0) to Week 24-11.6 ± 13.52-5.0 ± 14.00-13.3 ± 20.19
Week 6 to Week 24-7.6 ± 18.282.7 ± 5.51-1.8 ± 11.18
SecondaryChange in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24

Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) and Week 6 to Week 24
Reported as:
Mean · score on a scale
Change in SCI-PANSS Negative Symptom Score From Baseline (Wk 0) and Week 6 to Week 24
score on a scaleBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mg
Baseline (Wk 0) to Week 24-6.4 ± 3.85-5.0 ± 6.24-5.3 ± 9.64
Week 6 to Week 24-2.8 ± 4.09-1.3 ± 2.522.3 ± 4.19
SecondaryChange in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24

Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point scale with responses ranging from 1 (absent) to 7 (extreme). Higher values represent a worse outcome. The SCI-PANSS total score can range from 30 to 210. A negative change from baseline indicates improvement.

Time frame:
Baseline (Wk 0) and Week 6 to Week 24
Reported as:
Mean · score on a scale
Change in SCI-PANSS Negative Factor Score From Baseline (Wk 0) and Week 6 to Week 24
score on a scaleBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mg
Baseline (Wk 0) to Week 24-5.2 ± 4.09-6.7 ± 9.29-6.0 ± 9.76
Week 6 to Week 24-1.6 ± 3.78-1.0 ± 1.002.0 ± 4.16

Adverse events

Collected over All-cause mortality were reported from enrollment to the end of study. In the DBP, median time on follow up (median time subjects were followed) was 42.0 days (d) for all arms (DBP: Pbo, C 3mg, and C 6mg). In the BEP, median time on follow up was 117.5, 126.0, and 97.5d for BEP: C1.5mg, C 3mg, and C 6mg, respectively. In the SF DBP, median time on follow up was 57.0, 1.0, and 47.0d for SF DBP: Pbo, C 3mg, and C 6mg, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DBP Placebo0/16 (0%)0/16 (0%)12/16 (75%)
DBP Cariprazine 3 mg0/5 (0%)0/5 (0%)2/5 (40%)
DBP Cariprazine 6 mg0/13 (0%)0/13 (0%)10/13 (76.9%)
BEP Cariprazine 1.5 mg0/10 (0%)1/10 (10%)7/10 (70%)
BEP Cariprazine 3 mg0/4 (0%)1/4 (25%)3/4 (75%)
BEP Cariprazine 6 mg0/10 (0%)0/10 (0%)6/10 (60%)
SF DBP Placebo0/5 (0%)0/5 (0%)3/5 (60%)
SF DBP Cariprazine 3 mg0/1 (0%)0/1 (0%)0/1 (0%)
SF DBP Cariprazine 6 mg0/4 (0%)1/4 (25%)2/4 (50%)
SF BEP Cariprazine 1.5 mg0/10 (0%)0/10 (0%)4/10 (40%)
SF BEP Cariprazine 3 mg0/4 (0%)1/4 (25%)0/4 (0%)
SF BEP Cariprazine 6 mg0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent serious events
Most frequent serious events
EventDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mgSF DBP PlaceboSF DBP Cariprazine 3 mgSF DBP Cariprazine 6 mgSF BEP Cariprazine 1.5 mgSF BEP Cariprazine 3 mgSF BEP Cariprazine 6 mg
AGITATIONPsychiatric disorders0/160/50/130/101/40/100/50/10/40/100/40/10
SCHIZOPHRENIAPsychiatric disorders0/160/50/131/100/40/100/50/11/40/101/40/10
Most frequent other events
Showing 10 of 70
Most frequent other events
EventDBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgBEP Cariprazine 1.5 mgBEP Cariprazine 3 mgBEP Cariprazine 6 mgSF DBP PlaceboSF DBP Cariprazine 3 mgSF DBP Cariprazine 6 mgSF BEP Cariprazine 1.5 mgSF BEP Cariprazine 3 mgSF BEP Cariprazine 6 mg
COVID-19Infections and infestations0/160/50/134/100/41/101/50/10/40/100/40/10
EXTRAPYRAMIDAL DISORDERNervous system disorders0/162/50/130/100/40/100/50/10/40/100/40/10
AKATHISIANervous system disorders1/160/54/130/101/41/100/50/10/40/100/40/10
CONSTIPATIONGastrointestinal disorders1/161/52/131/100/41/100/50/11/40/100/40/10
WOUNDInjury, poisoning and procedural complications0/160/50/130/101/40/100/50/10/40/100/40/10
WEIGHT DECREASEDInvestigations0/160/51/130/101/40/100/50/10/41/100/40/10
MIGRAINENervous system disorders0/160/50/130/100/40/100/50/11/40/100/40/10
ANXIETYPsychiatric disorders0/160/50/130/101/40/100/50/10/40/100/40/10
LOGORRHOEAPsychiatric disorders0/160/50/130/101/40/100/50/10/40/100/40/10
SCHIZOPHRENIAPsychiatric disorders4/161/50/130/100/41/100/50/10/40/100/40/10

Baseline characteristics

Safety Population included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)DBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgTotal
Mean42.2 ± 11.7640.4 ± 13.7043.7 ± 10.8842.5 ± 11.40
Sex: Female, Male
Sex: Female, Male(Participants)DBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgTotal
Female61613
Male104721
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgTotal
Hispanic or Latino0000
Not Hispanic or Latino1651334
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgTotal
American Indian or Alaska Native0000
Asian1651334
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
SCI-PANSS Total Score at Baseline
SCI-PANSS Total Score at Baseline(score on a scale)DBP PlaceboDBP Cariprazine 3 mgDBP Cariprazine 6 mgTotal
Mean94.6 ± 8.7099.8 ± 8.1791.8 ± 7.3794.3 ± 8.33
08

Study locations

52 sites
  • Akita University Hospital /ID# 245941
    Akita, Akita 010-8543, Japan
  • International University of Health and Welfare Narita Hospital /ID# 243870
    Narita-shi, Chiba 2868520, Japan
  • Fukuoka University Hospital /ID# 244404
    Fukuoka, Fukuoka 814-0180, Japan
  • Kuramitsu Hospital /ID# 242511
    Fukuoka, Fukuoka 819-0037, Japan
  • Shiranui Hospital /ID# 243717
    Omuta-shi, Fukuoka 836-0004, Japan
  • Gifu University Hospital /ID# 246238
    Gifu, Gifu 501-1194, Japan
  • Holy Cross Hospital /ID# 242673
    Toki-shi, Gifu 509-5142, Japan
  • Hayakawa Clinic /ID# 242432
    Kure, Hiroshima 737-0111, Japan
  • National Hospital Organization Kure Medical Center /ID# 243405
    Kure-shi, Hiroshima 737-0023, Japan
  • Goryokai Hospital /ID# 242420
    Sapporo, Hokkaido 002-8029, Japan
  • Sapporo Medical University Hospital /ID# 245135
    Sapporo, Hokkaido 060-8543, Japan
  • Duplicate_Hokkaido University Hospital /ID# 243245
    Sapporo, Hokkaido 060-8648, Japan
  • Kagawa University Hospital /ID# 243772
    Kita-gun, Kagawa-ken 761-0793, Japan
  • Taniyama Hospital /ID# 242385
    Kagoshima, Kagoshima-ken 891-0111, Japan
  • Yokohama City University Hospital /ID# 244944
    Yokohama, Kanagawa 236-0004, Japan
  • Yuge Hospital /ID# 242849
    Kumamoto, Kumamoto 861-8002, Japan
  • Duplicate_University Hospital Kyoto Prefectural University of Medicine /ID# 242443
    Kyoto, Kyoto 602-8566, Japan
  • Maizuru Medical Center /ID# 243450
    Maizuru, Kyoto 625-8502, Japan
  • Mie University Hospital /ID# 244710
    Tsu, Mie-ken 514-8507, Japan
  • Mental Support Soyokaze Hospital /ID# 242512
    Ueda-shi, Nagano 386-0401, Japan
  • Nara Medical University Hospital /ID# 242561
    Kashihara-shi, Nara 634-8522, Japan
  • Asakayama General Hospital /ID# 242732
    Sakai, Osaka 590-0018, Japan
  • Hizen Psychiatric Center /ID# 243239
    Kanzaki-gun, Saga-ken 842-0192, Japan
  • Rainbow & Sea Hospital /ID# 242699
    Karatsu-shi, Saga-ken 847-0031, Japan
  • Inuo Hospital /ID# 243310
    Tosu-shi, Saga-ken 841-0081, Japan
  • Juntendo Univ Koshigaya Hospital /ID# 248502
    Koshigaya-shi, Saitama 343-0032, Japan
  • Numazu Chuo Hospital /ID# 245275
    Numazu-shi, Shizuoka 4108575, Japan
  • Tochigi Prefectural Okamotodai Hospital /ID# 248855
    Utsunomiya, Tochigi 329-1104, Japan
  • Tokushima University Hospital /ID# 250056
    Tokushima, Tokushima 770-8503, Japan
  • Narimasu Kosei Hospital /ID# 243107
    Banqiao Qu, Tokyo 175-0091, Japan
  • Ongata Hospital /ID# 256975
    Hachioji-shi, Tokyo 192-0153, Japan
  • Nishigahara Hospital /ID# 243312
    Kita-ku, Tokyo 114-0024, Japan
  • National Center of Neurology and Psychiatry /ID# 242677
    Kodaira-shi, Tokyo 187-8551, Japan
  • Tokyo Metropolitan Matsuzawa Hospital /ID# 245272
    Setagaya-ku, Tokyo 156-0057, Japan
  • Wakayama Medical University Hospital /ID# 251105
    Wakayama, Wakayama 641-8510, Japan
  • Shin-abuyama Hospital /ID# 243138
    Takatsuki, 569-1041, Japan
  • Minamitoyama Nakagawa Hospital /ID# 243616
    Toyama, 939-8073, Japan
  • Kaohsiung Municipal Kai-Syuan Psychiatric Hospital /ID# 241533
    Kaohsiung City, Kaohsiung 802, Taiwan
  • Bali Psychiatric Center /ID# 241597
    New Taipei City, New Taipei 249, Taiwan
  • Taipei Veterans General Hospital /ID# 241522
    Taipei City, Taipei 11217, Taiwan
  • Changhua Christian Hospital /ID# 241524
    Changhua City, Changhua County, 50006, Taiwan
  • National Taiwan University Hospital - Yunlin Branch /ID# 241537
    Douliu, 640, Taiwan
  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 241528
    Kaohsiung City, 807, Taiwan
  • TsaoTun Psychiatric Center, MOHW /ID# 246012
    Nantou City, 54249, Taiwan
  • New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical /ID# 243653
    New Taipei City, 236, Taiwan
  • Chung Shan Medical University Hospital /ID# 241543
    Taichung, 40201, Taiwan
  • Taichung Veterans General Hospital /ID# 246200
    Taichung, 40705, Taiwan
  • Jianan Psychiatric Center, Ministry of Health and Welfare /ID# 241540
    Tainan, 71742, Taiwan
  • Taipei City Hospital, Songde Branch /ID# 241600
    Taipei, 110, Taiwan
  • Tri-Service General Hospital Beitou Branch /ID# 241563
    Taipei, 112, Taiwan
  • Taoyuan Psychiatric Center, MOHW /ID# 241691
    Taoyuan, 33058, Taiwan
  • Linkou Chang Gung Memorial Hospital /ID# 241520
    Taoyuan City, 333, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Sep 2024, 25 months.

Results were first posted in Oct 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2022
First posted
May 10, 2022
StartActual
Aug 18, 2022
Primary completionActual
Sep 20, 2024
CompletionActual
Sep 20, 2024
Results first posted
Oct 20, 2025
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05368558
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 10, 2022
Start date
Aug 18, 2022
Primary completion
Sep 20, 2024
Completion
Sep 20, 2024
Results posted
Oct 20, 2025
Last update
Oct 20, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion